SCOPUS 정보 검색 플랫폼

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 3, 2004, Pages 277-280

Prodrugs as therapeutics

(1) Stella, Valentino J a

a UNIVERSITY OF KANSAS (United States)

Author keywords

Bioreversible derivative; Prodrug

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; AQUAVAN; CAMPTOTHECIN; CENTRAL NERVOUS SYSTEM AGENTS; DABIGATRAN ETEXILATE; GPI 15715; HORMONE DERIVATIVE; NITROUS OXIDE; OLMESARTAN; PACLITAXEL; PARECOXIB; PRODRUG; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; VALGANCICLOVIR; XIMELAGATRAN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ASIA; DRUG DELIVERY SYSTEM; DRUG INDUSTRY; DRUG METABOLISM; DRUG PENETRATION; DRUG RESEARCH; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; EDITORIAL; EUROPE; HEPATITIS; HEPATITIS VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERTENSION; ISCHEMIC HEART DISEASE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL LITERATURE; NORTH AMERICA; PAIN; PATENT; THROMBOSIS; VIRUS INFECTION;

EID: 1642296611 PISSN: 13543776 EISSN: None Source Type: Journal
DOI: 10.1517/13543776.14.3.277 Document Type: Editorial

Times cited : (74)

References (8)

1
- 35448936964
- To market, to market - 2001
- BERNARDELLI P, GAUDILLIERE B, VERGNE F: To market, to market - 2001. Ann. Rep. Med. Chem. (2002) 37:257-277.
- (2002) Ann. Rep. Med. Chem. , vol.37 , pp. 257-277
- Bernardelli, P.¹ Gaudilliere, B.² Vergne, F.³

2
- 1642343119
- To market, to market - 2002
- DOHERTY AM: To market, to market - 2002. Ann. Rep. Med. Chem. (2003) 38:347-374.
- (2003) Ann. Rep. Med. Chem. , vol.38 , pp. 347-374
- Doherty, A.M.¹

3
- 0031024171
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
- LIPINSKI CA, LOMBARDO F, DOMINY BW, FEENEY PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Del. Rev. (1997) 23:3-25.
- (1997) Adv. Drug Del. Rev. , vol.23 , pp. 3-25
- Lipinski, C.A.¹ Lombardo, F.² Dominy, B.W.³ Feeney, P.J.⁴

4
- 0034461768
- Drug-like properties and the causes of poor solubility and poor permeabitity
- LIPINSKI CA: Drug-like properties and the causes of poor solubility and poor permeabitity. J. Pharmacol. Tox. Meth. (2000) 44:235-249.
- (2000) J. Pharmacol. Tox. Meth. , vol.44 , pp. 235-249
- Lipinski, C.A.¹

5
- 3142646113
- Enabling strategies: Advancing new drug delivery concepts to gain the lead
- HORSPOOL KR, LIAINSKI CA: Enabling strategies: advancing new drug delivery concepts to gain the lead. Drug Del. Tech. (2003) 3(7):34-46.
- (2003) Drug Del. Tech. , vol.3 , Issue.7 , pp. 34-46
- Horspool, K.R.¹ Lipinski, C.A.²

6
- 0041343200
- Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI-15715 in volunteers
- FECHNER J, IHMSEN H, HATTERSCHEID D et al.: Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI-15715 in volunteers. Anesthesiology (2003) 99:303-313.
- (2003) Anesthesiology , vol.99 , pp. 303-313
- Fechner, J.¹ Ihmsen, H.² Hatterscheid, D.³

7
- 0037336416
- Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI-15715 in rats
- SCHYWALSKY M, IHMSEN H, TZABAZIS A et al.: Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI-15715 in rats. Eur. J. Anesthesiol. (2003) 20:182-190.
- (2003) Eur. J. Anesthesiol. , vol.20 , pp. 182-190
- Schywalsky, M.¹ Ihmsen, H.² Tzabazis, A.³

8
- 0141750717
- Oral direct thrombin inhibitors in clinical development
- GUSTAFSSON D: Oral direct thrombin inhibitors in clinical development. J. Int. Med. (2003) 254:322-334.
- (2003) J. Int. Med. , vol.254 , pp. 322-334
- Gustafsson, D.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.